Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Clinical trial NCT03515837 · COMPLETED
Trial details
- NCT number
- NCT03515837
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-29
- Primary completion
- 2023-01-17
- Enrollment
- 492
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.